Screener
DaVita DVA D&A
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by DaVita in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: DaVita’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 5:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000927066-26-000062
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Patient care costs | 2,342,257 | 2,239,660 |
| General and administrative | 421,914 | 374,090 |
| Depreciation and amortization | 177,829 | 176,451 |
| Equity investment income, net | (8,344) | (5,609) |
| Total operating expenses | 2,933,656 | 2,784,592 |
| Operating income | 481,892 | 438,937 |
| Debt expense | (145,131) | (135,055) |
Item 1. Condensed Consolidated Financial Statements:
FAQ
- What is DaVita's D&A?
- DaVita (DVA) reported D&A of $177.83M in Q1 2026.
- How has DaVita's D&A changed year-over-year?
- DaVita's D&A increased by 0.8% year-over-year, from $176.45M to $177.83M.
- What is the long-term trend for DaVita's D&A?
- Over 4 years (2021 to 2025), DaVita's D&A has grown at a 1.3% compound annual growth rate (CAGR), from $680.62M to $715.35M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about DaVita's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude